Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | CES2 | O00748 | 4/20 | 0.35 |
| ▸ | CES1 | P23141 | 4/20 | 0.35 |
| ▸ | CASP3 | P42574 | 2/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12213944 | 0.84 | MAPT (0.42) | MAPTALDH1A1KDM4EHTTCA1 | |
| SCHEMBL12831909 | 0.84 | PKM (0.31) | — | |
| SCHEMBL27494904 | 0.81 | MAPT (0.40) | MAPTALDH1A1KDM4EHTTCA1 | |
| SCHEMBL27494903 | 0.81 | MAPT (0.40) | MAPTALDH1A1KDM4EHTTCA1 | |
| SCHEMBL19484370 | 0.78 | MAPT (0.41) | MAPTALDH1A1KDM4EHTTCA1 | |
| SCHEMBL29056376 | 0.75 | MAPT (0.40) | MAPTALDH1A1KDM4EHTTCA1 | |
| SCHEMBL19749188 | 0.75 | ALDH1A1 (0.40) | MAPTALDH1A1KDM4EHTTCA1 | |
| SCHEMBL22381468 | 0.75 | MAPT (0.37) | MAPTALDH1A1KDM4EHTTCA1 | |
| SCHEMBL18697369 | 0.74 | CA1 (0.44) | MAPTALDH1A1KDM4EHTTCA1 | |
| SCHEMBL2153565 | 0.74 | CA1 (0.44) | MAPTALDH1A1KDM4EHTTCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793895-B2 | Residualizing linkers and uses thereof | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION | 2023-10-24 | — | — | US | disclosed |
| US-20210060190-A1 | RESIDUALIZING LINKERS AND USES THEREOF | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2021-03-04 | — | — | US | disclosed |
| US-7910222-B2 | Polymerizable composition for forming optical device, optical device and method for producing optical device | FUJIFILM CORPORATION (JP) | 2011-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210060190-A1 | RESIDUALIZING LINKERS AND USES THEREOF | CD44, CD47, MTCL3 | MAPT 1318/4885ALDH1A1 619/4885KDM4E 937/4885 |
| US-11793895-B2 | Residualizing linkers and uses thereof | CD44, CD47, MTCL3 | MAPT 1318/4885ALDH1A1 619/4885KDM4E 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.